Meridian Investment Counsel Inc. trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.3% during the first quarter, HoldingsChannel reports. The firm owned 11,865 shares of the company’s stock after selling 400 shares during the quarter. Meridian Investment Counsel Inc.’s holdings in Novo Nordisk A/S were worth $621,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in NVO. Boston Partners bought a new position in shares of Novo Nordisk A/S during the fourth quarter worth $99,963,000. Fisher Asset Management LLC boosted its position in shares of Novo Nordisk A/S by 2.9% during the fourth quarter. Fisher Asset Management LLC now owns 14,202,935 shares of the company’s stock worth $654,329,000 after purchasing an additional 405,531 shares in the last quarter. Avalon Advisors LLC boosted its position in shares of Novo Nordisk A/S by 494.7% during the fourth quarter. Avalon Advisors LLC now owns 422,932 shares of the company’s stock worth $19,484,000 after purchasing an additional 351,810 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of Novo Nordisk A/S by 897.5% during the fourth quarter. Two Sigma Advisers LP now owns 278,300 shares of the company’s stock worth $12,821,000 after purchasing an additional 250,400 shares in the last quarter. Finally, CIBC Asset Management Inc bought a new position in shares of Novo Nordisk A/S during the fourth quarter worth $11,418,000. 7.04% of the stock is currently owned by institutional investors.
NVO traded down $0.37 on Tuesday, reaching $47.00. The company had a trading volume of 26,058 shares, compared to its average volume of 1,387,776. Novo Nordisk A/S has a fifty-two week low of $41.23 and a fifty-two week high of $52.83. The firm has a market cap of $114.55 billion, a P/E ratio of 18.63, a price-to-earnings-growth ratio of 2.17 and a beta of 0.56. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.79 and a current ratio of 0.96.
TRADEMARK VIOLATION NOTICE: This news story was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://dakotafinancialnews.com/2019/05/14/novo-nordisk-a-s-nvo-stake-decreased-by-meridian-investment-counsel-inc.html.
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.